Occlusive blood clots remain a significant global health challenge and result in emergencies that are main causes of death and disability worldwide. Thrombolytic agents (including tissue plasminogen activator, tPA) are the only pharmacological means to dissolve blood clots. However, these drugs have modest efficacy and severe safety concerns persist. We have developed light-responsive tPA-loaded red blood cells (tPA-RBCs^Photo) to target thrombolytic activity at the site of a blood clot. Herein, we describe the use of light to control the release of tPA from engineered RBCs and the subsequent degradation of a blood clot ex vivo. Furthermore, we have employed this technology to restore blood flow to an occluded mouse artery in vivo using a targeted dose that is 25 times lower than conventional systemic tPA treatment.

中文翻译：

---

光溶栓剂：一种靶向裂解血栓的光驱动技术


闭塞性血栓仍然是一项重大的全球健康挑战，并导致紧急情况成为全球死亡和残疾的主要原因。溶栓剂（包括组织纤溶酶原激活剂，tPA）是溶解血凝块的唯一药理学手段。然而，这些药物的疗效不大，严重的安全问题仍然存在。我们开发了光反应性 tPA 负载红细胞 （tPA-RBC ^Photo ） 来靶向血凝块部位的溶栓活性。在本文中，我们描述了使用光来控制工程红细胞中 tPA 的释放以及随后的体外血凝块降解。此外，我们采用这项技术，使用比常规全身 tPA 治疗低 25 倍的靶向剂量在体内恢复流向闭塞小鼠动脉的血流。